Related Experiment Video
Updated: Aug 23, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Dopamine and iron in the pathophysiology of restless legs syndrome (RLS)
1Neurology and Sleep Medicine, Johns Hopkins Bayview Medical Center, Asthma and Allergy Bldg 1B46b, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA. richardjhu@aol.com
Background And Purpose:
The evaluation of the pathophysiology of restless legs syndrome (RLS) stems largely from recognition of the information provided by both pharmacological treatment of the disorder and the secondary forms of the disorder. This article examines the pathophysiological implications of each of these clinical aspects of RLS.
Patients And Methods:
The article reviews the existing literature in relation to possible pathology suggested by the clinical data. It will then explore other data supporting each of the possible pathologies and examine the relationships between these pathologies.
Results:
The pharmacological treatment data strongly support a dopaminergic abnormality for RLS. Other pharmacological data and some imaging data also support this, although the data are not entirely consistent. The secondary forms of RLS strongly support an iron deficiency abnormality for RLS, further documented by several other studies. Some animal studies have shown a relation between iron deficiency and dopaminergic abnormalities that have some similarity to those seen in the RLS patient.
Conclusions:
It is concluded that there may be an iron-dopamine connection central to the pathophysiology of RLS for at least some if not most patients with this disorder.
Related Concept Videos
Parkinson Disease ll: Pathophysiology
Parkinson Disease l: Introduction
Alterations in Muscle Tone lll
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Parkinson's Disease: Overview

